Genetic predisposition to adverse consequences of anti–cholinesterases in ‘atypical’ BCHE carriers
暂无分享,去创建一个
David Glick | Hermona Soreq | B. No̸rgaard-Pedersen | H. Soreq | D. Glick | Bent Nørgaard-Pedersen | Yael Loewenstein-Lichtenstein | Mikael Schwarz | Haim Zakut | H. Zakut | Y. Loewenstein-Lichtenstein | M. Schwarz
[1] C. P. Nogueira,et al. Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[2] R. Davies,et al. The activity of various esterase inhibitors towards atypical human serum cholinesterase , 1959 .
[3] H. Soreq,et al. Engineering of human cholinesterases explains and predicts diverse consequences of administration of various drugs and poisons. , 1995, Pharmacology & therapeutics.
[4] J. Rosenbusch,et al. Acetylcholinesterase from human erythrocyte membranes: dimers as functional units , 1982, FEBS letters.
[5] O. Lockridge. Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine. , 1990, Pharmacology & therapeutics.
[6] O. Lockridge,et al. Comparison of butyrylcholinesterase and acetylcholinesterase. , 1989, The Biochemical journal.
[7] A. Gnatt,et al. Intramolecular relationships in cholinesterases revealed by oocyte expression of site‐directed and natural variants of human BCHE. , 1992, The EMBO journal.
[8] Y. Sharabi,et al. Survey of symptoms following intake of pyridostigmine during the Persian Gulf war. , 1991, Israel journal of medical sciences.
[9] J. Sussman,et al. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[10] H. Soreq,et al. Synaptic and epidermal accumulations of human acetylcholinesterase are encoded by alternative 3'-terminal exons , 1995, Molecular and cellular biology.
[11] M. Winker. Tacrine for Alzheimer's disease. Which patient, what dose? , 1994, JAMA.
[12] D. May. Genetic Differences in Drug Disposition , 1994, Journal of clinical pharmacology.
[13] J L Sussman,et al. Conversion of acetylcholinesterase to butyrylcholinesterase: modeling and mutagenesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[14] L. Iversen. Chapter 51: Approaches to cholinergic therapy in Alzheimer's disease , 1993 .
[15] H. Gavaghan. NIH panel rejects Persian Gulf Syndrome , 1994, Nature.
[16] A. Nordberg,et al. Pharmacokinetic studies of cholinesterase inhibitors , 1993, Acta neurologica Scandinavica. Supplementum.
[17] C. P. Nogueira,et al. Phenotypic and molecular biological analysis of human butyrylcholinesterase variants. , 1990, Clinical biochemistry.
[18] J R Keeler,et al. Pyridostigmine used as a nerve agent pretreatment under wartime conditions. , 1991, JAMA.
[19] O. Lockridge,et al. Prediction of drug sensitivity in individuals with atypical serum cholinesterase based on in vitro biochemical studies. , 1981, Biochemical pharmacology.
[20] H. Boddeke,et al. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. , 1993, Progress in brain research.
[21] E. Giacobini. The Second Generation of Cholinesterase Inhibitors: Pharmacological Aspects , 1991 .
[22] B. No̸rgaard-Pedersen,et al. Successive organophosphate inhibition and oxime reactivation reveals distinct responses of recombinant human cholinesterase variants. , 1995, Brain research. Molecular brain research.
[23] H. Berman,et al. Interaction of tetrahydroaminoacridine with acetylcholinesterase and butyrylcholinesterase. , 1992, Molecular Pharmacology.
[24] B. Kerem,et al. Population diversity and distinct haplotype frequencies associated with ACHE and BCHE genes of Israeli Jews from trans-Caucasian Georgia and from Europe. , 1994, Genomics.